Jorge Rojas-Rivera
Overview
Explore the profile of Jorge Rojas-Rivera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rojas-Rivera J, Carriazo S, Ortiz A
N Engl J Med
. 2022 Dec;
387(26):2481-2482.
PMID: 36577110
No abstract available.
2.
Villalvazo P, Carriazo S, Rojas-Rivera J, Ramos A, Ortiz A, Perez-Gomez M
Clin Kidney J
. 2022 Nov;
15(11):1973-1980.
PMID: 36324999
Systemic lupus erythematosus (SLE) is a chronic and inflammatory autoimmune disease of unknown origin that may cause kidney disease, i.e. lupus nephritis (LN). Within a wider trend towards an expanding...
3.
Rojas-Rivera J, Fervenza F, Ortiz A
Drugs
. 2021 Dec;
82(2):109-132.
PMID: 34932208
Immunosuppressive therapy is mandatory for primary membranous nephropathy with persistent nephrotic proteinuria or anti-phospholipase A2 receptor antibodies, reduced kidney function, or another risk factor for progression. Rituximab has demonstrated efficacy...
4.
Fernandez-Juarez G, Rojas-Rivera J, Praga M
Kidney Int
. 2021 Apr;
99(5):1243.
PMID: 33892866
No abstract available.
5.
Fernandez-Juarez G, Rojas-Rivera J, Praga M
Kidney Int
. 2021 Mar;
99(4):1024-1025.
PMID: 33745533
No abstract available.
6.
Avello A, Fernandez-Prado R, Santos-Sanchez-Rey B, Rojas-Rivera J, Ortiz A
Clin Kidney J
. 2021 Feb;
14(1):18-22.
PMID: 33564403
Nephrologists are familiar with severe cases of anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) presenting as rapidly progressive glomerulonephritis. However, less is known about AAV with slowly progressive renal involvement. While its...
7.
Rojas-Rivera J, Ortiz A, Carriazo S
N Engl J Med
. 2021 Jan;
384(2):187.
PMID: 33497557
No abstract available.
8.
Fernandez-Juarez G, Rojas-Rivera J, Logt A, Justino J, Sevillano A, Caravaca-Fontan F, et al.
Kidney Int
. 2020 Nov;
99(4):986-998.
PMID: 33166580
A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical...
9.
Egido J, Rojas-Rivera J, Mas S, Ruiz-Ortega M, Sanz A, Gonzalez Parra E, et al.
Expert Opin Investig Drugs
. 2017 May;
26(6):741-750.
PMID: 28468519
Endothelin-1 (ET-1) is the most potent vasoconstrictor, and is involved in the renal regulation of salt and water homeostasis. When produced in excess in the kidney, ET-1 promotes proteinuria and...
10.
Cavero T, Rabasco C, Lopez A, Roman E, Avila A, Sevillano A, et al.
Nephrol Dial Transplant
. 2017 Mar;
32(3):466-474.
PMID: 28339660
Background: Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with...